Skip to Content
Merck
  • Delirious mania: detection, diagnosis, and clinical management in the acute setting.

Delirious mania: detection, diagnosis, and clinical management in the acute setting.

Journal of psychiatric practice (2013-01-22)
Natalie L Jacobowski, Stephan Heckers, William V Bobo
ABSTRACT

Delirious mania is a severe but under-recognized neuropsychiatric syndrome characterized by the rapid onset of delirium, mania, and psychosis, not associated with a prior toxicity, physical illness, or mental disorder. Catatonia is often a prominent feature of the syndrome. While initially believed to be rare, recent reports suggest that delirious mania may constitute up to 15% of all acute mania cases. When delirious mania is unrecognized or improperly treated, it can progress rapidly in severity and can become life-threatening. This article reviews the pathophysiology, diagnosis, and treatment of delirious mania and includes a detailed case report. Delirious mania is robustly responsive to high-dose lorazepam or electroconvulsive therapy (ECT); thus, early recognition and definitive treatment can be life-saving.

MATERIALS
Product Number
Brand
Product Description

Lorazepam, European Pharmacopoeia (EP) Reference Standard
Lorazepam for system suitability, European Pharmacopoeia (EP) Reference Standard
Supelco
Lorazepam solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
(±)-Lorazepam